Yonina Murciano-Goroff

Opinions are my own.

[Yonina Murciano-Goroff @YoninaMG]

Our paper in @Nature demonstrates diverse alterations leading to resistance to G12C inhibition. We must continue to work to advance treatments on behalf of our patients with KRAS mutant cancers https://t.co/JUmm4mjsVL

[MSK Department of Medicine @MSK_DeptOfMed]

At #ESMO25, join @YoninaMG to learn about the results of a phase 1 study that evaluated telisotuzumab adizutecan in patients with MET-amplified advanced solid tumors. @MSKCancerCenter @myESMO

Learn more: https://t.co/g3FYOnS7Ei

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Dr. Yonina Murciano-Goroff (@YoninaMG) studies early drug development for #cancer. At #AACR23, she shared new research into how she's using biomarkers and genomic data from MSK-IMPACT® to identify effective treatments for patients.

[Yonina Murciano-Goroff @YoninaMG]

Selpercatinib in the neoadjuvant setting for RET fusion + NSCLC: https://t.co/tHMZhXp0Wg

[Yonina Murciano-Goroff @YoninaMG]

@JTOonline @alexdrilon A great collaboration aimed at preventing RET fusion + CNS mets in NSCLC. https://t.co/IcFUezC2bW @alexdrilon @AlexiaIasonos

[Yonina Murciano-Goroff @YoninaMG]

@SewantiLimaye @ullas_batra @RAJATRAJ @MSKCancerCenter @RonaYaeger @RFhospital A rockstar international team addressing a critically important topic for patients! - @CDebyaniPhD Dr. Greg Riely @RonaYaeger @DrMrinalGounder @SewantiLimaye @ullas_batra @RAJATRAJ @bhuvanchugh Dr. Vijay Agarwal

[Yonina Murciano-Goroff @YoninaMG]

@oncmom17 @MSKCancerCenter I learn so much from @oncmom17 and am ever grateful to be her colleague as well!

[Yonina Murciano-Goroff @YoninaMG]

@CDebyaniPhD @OncoKB @cbioportal I had the best company for dinner, and it's inspiring to see all of the transformative work coming out of this group! @CDebyaniPhD @OncoKB @cbioportal

[MSK Department of Medicine @MSK_DeptOfMed]

Today at #AACR23, @YoninaMG will present results of a first-in-human phase 1 study of LY3537982 — a highly selective #KRAS G12C inhibitor in people with advanced solid tumors with this mutation — at 2:35 in the Chaplin Theater. https://t.co/kMTCvnno5O

[Stephen V Liu, MD @StephenVLiu]

Drs. @YoninaMG @alexdrilon and team report on CNS disease in #RET fusion-positive NSCLC with selpercatinib @JTOonline. In pts with CNS metastases, only 20% with CNS progression at 3y. In pts without brain metastases, 0% (!) had CNS metastases at 3y. #LCSM

https://t.co/DjgitIQoNF

[Yonina Murciano-Goroff @YoninaMG]

RT: Featured today by @MSKLibrary: Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies https://t.co/XMTHAN7cR6

[NatureRevClinOncol @NatRevClinOncol]

The fourth most visited short article published in @natrevclinoncol in 2022 is: https://t.co/laff7rggeQ

[Chai Bandlamudi @chaiband]

Fantastic collaboration with @YoninaMG, @alexdrilon, @MFBerger1, @StadlerZsofia and @MskccCMO.

We analyze our #MSKIMPACT clinical sequencing cohort for evidence of germline BRCA1/2 mediated tumorigenesis in non-BRCA-associated cancers. 1/5

[Yonina Murciano-Goroff @YoninaMG]

Our work on BRCA1/2 reversion mutations in a pan-cancer cohort reveals a BRCA-mediated phenotype in non-canonical histologies. Kudos to a great team! @alexdrilon @chaiband @AliSchram @YJanjigianMD @StadlerZsofia @MFBerger1 https://t.co/Tx4tXTNwKA

[Yonina Murciano-Goroff @YoninaMG]

Great work on KRAS G12C! https://t.co/w2KXlbzP3W

[Sandra Misale @Sandra_Misale]

Huge thanks and Kudos to all the authors and collaborators @RonaYaeger @Rosenlab1 @LoweLabMSKCC @r_mezzadra @DSolit @MFBerger1 @YoninaMG @Mirati @BoundlessBio 💪💪💪and @CD_AACR and Michele Hartsough for the amazing work together! Ad Maiora!

[Emily Lebow, MD @EmilyLebow]

Excited to share work done with many collaborators @MSKCancerCenter and showing that ctDNA testing expands access to life-prolonging therapy for patients with lung cancer! @MSK_RadOnc https://t.co/dmC1MSBay5

[Alexander Drilon MD @alexdrilon]

Hello, 3rd ed! The print version is out in a few weeks. The digital version is available now on Kindle and other e-readers. Congratulations to @NouraChoudhury @YoninaMG @NeilVasan and the many contributing authors!! https://t.co/25d7fehfrn

[MSK CME @MSKCME]

#Genetics has become an integral part of #cancercare. Dr. Zsofia K. Stadler & Kelsey Breen invite you to the Hereditary Cancer Genetics course @MSKCancerCenter featuring expert faculty in #hereditarycancer syndromes: https://t.co/kjClTgJM8o

Register at: https://t.co/CKbIBXrY7e

[ACS Journal Cancer @JournalCancer]

New! Although positive germline findings are prevalent in diverse, pan-cancer patients, Black patients are less likely to get recommended genetics care compared to White patients—and this disparity could affect cancer outcomes and families. https://t.co/XJ8G5BTlMY CC: @OncoAlert

[Yonina Murciano-Goroff @YoninaMG]

Important to have clinical trial options for patients with PTHS / germline PTEN mutant tumors https://t.co/fKBf1V4JqD